In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...
Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback